Download PDF

FOR IMMEDIATE RELEASE

Lumiphore-Cisbio Partnership a Solid Success: First of Many on Company's Roadmap

Lumiphore points to Cisbio product launch as strategy validation for boosting research discovery through superior fluorescence technology

Richmond, California – April 8, 2008 – Lumiphore, the leader in ultra-bright lanthanide fluorescence technology driving new biological research discovery, today laid out a roadmap for expanding the technology’s penetration into additional commercial markets. This roadmap is founded upon the success of their partnership with Cisbio, who this week introduced a new line of high performance lanthanide fluorescence assay products for the drug discovery market based on Lumiphore technology.

“The Cisbio relationship and business model are working well for both companies, as witnessed by this week’s announcement and the strong early interest in the products,” said Ken Raymond, Lumiphore President and Chairman of the Board of Directors. “This is great validation for our approach of focusing on the technology and partnering with market leaders who have deep presence with end user customers in specific application areas.”

The versatility of Lumiphore’s lanthanide fluorescence complexes in Cisbio assays allows them to be easily incorporated into current high through-put drug development processes, where they deliver a number of significant advantages based on a more than tenfold increase in brightness over competing lanthanide compounds.

The company stated that drug discovery is only one of the many areas where Lumiphore’s brightness and ease of use will enable faster, more cost effective use, and the ability to discover and analyze previously undetectable biological and diagnostic events.

“We are in discussions with a variety of potential partners and licensees who are excited about the possibilities for new discovery in other areas of biological and diagnostic research opened up by a validated lanthanide technology that delivers an order of magnitude improvement in brightness,” said Raymond. “Lumiphore’s proven technology and deep patent protection provide a compelling business opportunity for these companies to expand the strength and competitiveness of their product offerings.”

Lumiphore is currently pursuing partnerships in rapid homogeneous diagnostics and a variety of DNA applications, with particular interest in firms who can facilitate the multiple facets of a total solution integrating TRF detection equipment and reagent capabilities directly into large markets where needs are currently unmet.

Interested parties are encouraged to contact Stephen Blose, Lumiphore’s Chief Business Development Officer at steve@lumiphore.com or (510) 232-8455.

About Lumiphore
Lumiphore is the pioneering leader in state-of-the-art lanthanide fluorescence detection technology. The company’s patented, ultra-bright Lumi4™ lanthanides vastly improve and accelerate scientific discovery, diagnostics and research—particularly TRF (time-resolved fluorescence)—because they are an order of magnitude brighter than competing lanthanides and they are extremely stable and easy to use. Lumi4™ lanthanides enable the discovery of new substances and interactions that were previously undetectable while reducing time and cost. The technology is well suited to a wide variety of research areas, including drug discovery, diagnostics and commercial DNA applications. The company’s products reach end user customers through partners and licensees who are leading suppliers and developers of high-value products in many biotechnology markets.. Lumiphore owns exclusive rights to the original technology patents from the University of California Berkeley, and retains the original inventors as key contributors to the firm. Further information is available on the company’s web site www.lumiphore.com.

For further information contact:

Stephen Blose | Chief Business Development Officer
Lumiphore Inc.
4677 Meade Street, Suite 216
Richmond, California 94804-4603
(510) 232-8455 TEL / FAX
steve@lumiphore.com
www.lumiphore.com